6 news items
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
RVMD
5 Jun 24
Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
to the termination of the company's collaboration agreement with Sanofi in 2023. R&D Expenses: Research
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
RVMD
1 May 24
.Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
9 Apr 24
for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors
eig7sbof99gy30x7smm
RVMD
4 Apr 24
.Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline
- Prev
- 1
- Next